Identification of VRK1 as a Novel Potential Biomarker for Prognosis and Immunotherapy in Hepatocellular Carcinoma

References

• Campillo-Marcos I, García-González R, Navarro-Carrasco E, Lazo PA. The human VRK1 chromatin kinase in cancer biology. Cancer Lett. 2021;503:117–128. doi:10.1016/j.canlet.2020.12.032
   PubMed Web of Science ®Google Scholar
• Kim W, Chakraborty G, Kim S, et al. Macro histone H2A1.2 (macroH2A1) protein suppresses mitotic kinase VRK1 during interphase. J Biol Chem. 2012;287(8):5278–5289.
   PubMed Web of Science ®Google Scholar
• Wu J, Li T, Ji H, Chen Z, Zhai B. VRK1 predicts poor prognosis and promotes bladder cancer growth and metastasis in vitro and in vivo. Front Pharmacol. 2022;13:874235. doi:10.3389/fphar.2022.874235
   PubMed Web of Science ®Google Scholar
• Du N, Zhang B, Zhang Y. Downregulation of VRK1 inhibits progression of lung squamous cell carcinoma through DNA damage. Can Respir J. 2023;2023:4533504. doi:10.1155/2023/4533504
   PubMed Web of Science ®Google Scholar
• Chang X, Tamauchi S, Yoshida K, et al. Downregulating vaccinia-related kinase 1 by luteolin suppresses ovarian cancer cell proliferation by activating the p53 signaling pathway. Gynecologic Oncol. 2023;173:31–40. doi:10.1016/j.ygyno.2023.04.003
   PubMed Web of Science ®Google Scholar
• Lee N, Kwon JH, Kim YB, et al. Vaccinia-related kinase 1 promotes hepatocellular carcinoma by controlling the levels of cell cycle regulators associated with G1/S transition. Oncotarget. 2015;6(30):30130–30148. doi:10.18632/oncotarget.4967
   PubMedGoogle Scholar
• Zhang G. Regulatory T-cells-related signature for identifying a prognostic subtype of hepatocellular carcinoma with an exhausted tumor microenvironment. Front Immunol. 2022;13:975762. doi:10.3389/fimmu.2022.975762
   PubMed Web of Science ®Google Scholar
• Gentles AJ, Newman AM, Liu CL, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nature Med. 2015;21(8):938–945. doi:10.1038/nm.3909
   PubMed Web of Science ®Google Scholar
• Aran D, Hu Z, Butte AJ. xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol. 2017;18(1):220. doi:10.1186/s13059-017-1349-1
   PubMed Web of Science ®Google Scholar
• Zhu K, Xiaoqiang L, Deng W, Wang G, Fu B. Development and validation of a novel lipid metabolism-related gene prognostic signature and candidate drugs for patients with bladder cancer. Lipids Health Dis. 2021;20(1):146. doi:10.1186/s12944-021-01554-1
   PubMed Web of Science ®Google Scholar
• Li T, Fan J, Wang B, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77(21):e108–e110. doi:10.1158/0008-5472.CAN-17-0307
   PubMed Web of Science ®Google Scholar
• Reinhold WC, Sunshine M, Liu H, et al. CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set. Cancer Res. 2012;72(14):3499–3511. doi:10.1158/0008-5472.CAN-12-1370
   PubMed Web of Science ®Google Scholar
• Du A, Li S, Zhou Y, et al. M6A-mediated upregulation of circMDK promotes tumorigenesis and acts as a nanotherapeutic target in hepatocellular carcinoma. Mol Cancer. 2022;21(1):109. doi:10.1186/s12943-022-01575-z
   PubMed Web of Science ®Google Scholar
• Liu P, Kong L, Liu Y, Li G, Xie J, Lu X. A key driver to promote HCC: cellular crosstalk in tumor microenvironment. Front Oncol. 2023;13:1135122. doi:10.3389/fonc.2023.1135122
   PubMed Web of Science ®Google Scholar
• Jiang D, Ma X, Zhang X, et al. New techniques: a roadmap for the development of HCC immunotherapy. Front Immunol. 2023;14:1121162. doi:10.3389/fimmu.2023.1121162
   PubMed Web of Science ®Google Scholar
• Wu X, Peng M, Huang B, et al. Immune microenvironment profiles of tumor immune equilibrium and immune escape states of mouse sarcoma. Cancer Lett. 2013;340(1):124–133. doi:10.1016/j.canlet.2013.07.038
   PubMed Web of Science ®Google Scholar
• Song H, Huang XF, Hu SY, Lu LL, Yang XY. The LINC00261/MiR105-5p/SELL axis is involved in dysfunction of B cell and is associated with overall survival in hepatocellular carcinoma. PeerJ. 2022;10:e12588. doi:10.7717/peerj.12588
   PubMed Web of Science ®Google Scholar
• Bai X, Zhou Y, Yokota Y, et al. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade. J Exp Clin Cancer Res. 2022;41(1):132. doi:10.1186/s13046-022-02307-3
   PubMed Web of Science ®Google Scholar
• Wang H, Zhang H, Wang Y, et al. Regulatory T-cell and neutrophil extracellular trap interaction contributes to carcinogenesis in non-alcoholic steatohepatitis. J Hepatol. 2021;75(6):1271–1283. doi:10.1016/j.jhep.2021.07.032
   PubMed Web of Science ®Google Scholar
• Pang N, Shi J, Qin L, et al. IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin. J Hematol Oncol. 2021;14(1):118. doi:10.1186/s13045-021-01128-9
   PubMed Web of Science ®Google Scholar
• Ning WR, Jiang D, Liu XC, et al. Carbonic anhydrase XII mediates the survival and prometastatic functions of macrophages in human hepatocellular carcinoma. J Clin Invest. 2022;132(7). doi:10.1172/JCI153110
   PubMed Web of Science ®Google Scholar
• Yau T, Park JW, Finn RS, et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (checkmate 459): a randomised, multicentre, open-label, Phase 3 trial. Lancet Oncol. 2022;23(1):77–90. doi:10.1016/S1470-2045(21)00604-5
   PubMed Web of Science ®Google Scholar
• Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. New Engl J Med. 2020;382(20):1894–1905. doi:10.1056/NEJMoa1915745
   PubMed Web of Science ®Google Scholar
• Li D, Li K, Zhang W, et al. The m6A/m5C/m1A regulated gene signature predicts the prognosis and correlates with the immune status of hepatocellular carcinoma. Front Immunol. 2022;13:918140. doi:10.3389/fimmu.2022.918140
   PubMed Web of Science ®Google Scholar
• Choudhury AD. PTEN-PI3K pathway alterations in advanced prostate cancer and clinical implications. Prostate. 2022;82(Suppl 1):S60–s72. doi:10.1002/pros.24372
   PubMedGoogle Scholar
• Sweeney CJ, Percent IJ, Babu S, et al. Phase Ib/II study of enzalutamide with samotolisib (LY3023414) or placebo in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res. 2022;28(11):2237–2247. doi:10.1158/1078-0432.CCR-21-2326
   PubMed Web of Science ®Google Scholar
• Rubinstein MM, Hyman DM, Caird I, et al. Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway. Cancer. 2020;126(6):1274–1282. doi:10.1002/cncr.32677
   PubMed Web of Science ®Google Scholar
• Chiorean EG, Picozzi V, Li CP, et al. Efficacy and safety of abemaciclib alone and with PI3K/mTOR inhibitor LY3023414 or galunisertib versus chemotherapy in previously treated metastatic pancreatic adenocarcinoma: a randomized controlled trial. Cancer Med. 2023;12(20):20353–20364. doi:10.1002/cam4.6621
   PubMed Web of Science ®Google Scholar
• Zou Y, Ge M, Wang X. Targeting PI3K-AKT-mTOR by LY3023414 inhibits human skin squamous cell carcinoma cell growth in vitro and in vivo. Biochem Biophys Res Commun. 2017;490(2):385–392. doi:10.1016/j.bbrc.2017.06.052
   PubMed Web of Science ®Google Scholar
• Zha JH, Xia YC, Ye CL, et al. The anti-non-small cell lung cancer cell activity by a mtor kinase inhibitor PQR620. Front Oncol. 2021;11:669518. doi:10.3389/fonc.2021.669518
   PubMedGoogle Scholar
• Tarantelli C, Gaudio E, Hillmann P, et al. The novel TORC1/2 kinase inhibitor PQR620 has anti-tumor activity in lymphomas as a single agent and in combination with venetoclax. Cancers. 2019;11(6):775. doi:10.3390/cancers11060775
   PubMed Web of Science ®Google Scholar